Documentos de Keltai M. | REDI

Regresar

Mostrando 4 resultados de: 4

Filtros aplicados

Palabras Claves: "Cardiovascular disease"

Subtipo de publicación

Publisher

European Heart Journal(2)

Cardiovascular Diabetology(1)

Diabetes, Obesity and Metabolism(1)

Área temáticas

Enfermedades(3)

Farmacología y terapéutica(2)

Fisiología humana(2)

Medicina y salud(2)

Ginecología, obstetricia, pediatría, geriatría(1)

Área de conocimiento

Medicina interna(4)

Enfermedad cardiovascular(2)

Año de Publicación

Origen

Palabras Claves

Clinical trial(1)

GLP-1 receptor agonist(1)

GLP-1-based therapy(1)

Glucagon like peptide-1 receptor agonists(1)

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

Abstract: The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human gluca

Palabras claves:

antidiabetic drug, Cardiovascular disease, Clinical trial, diabetes complications, GLP-1 receptor agonist

Atisso C.M., Avezum A.J., Basile J.N., Cardona-Munoz E.G., Chung N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., DIaz R., Franek E., Gerstein H.C., Hâncu N., Hanefeld M., Holt S., Jansky P., Keltai M., Lakshmanan M., Lanas F., Leiter L.A., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.

Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

Abstract: Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) e

Palabras claves:

Cardiovascular disease, Primary Prevention, statins

Avezum A.J., Bosch J.J., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Joseph P.G., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.

Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin

Abstract: Objective : Recent European Guidelines for Diabetes, Pbkp_rediabetes and Cardiovascular Diseases int

Palabras claves:

Cardiovascular disease, GLP-1-based therapy, Metformin, Morbidity, Mortality

Avezum A.J., Basile J.N., Colhoun H.M., Cushman W.C., Dagenais G.R., DIaz R., Dyal L., Ferrannini G., Gerstein H.C., Jansky P., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Mellbin L., Pais P., PATRICIO LOPEZ -JARAMILLO, PīrCrossed D Sign gs V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H.

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

Abstract: Background: The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double

Palabras claves:

Cardiovascular disease, Glucagon like peptide-1 receptor agonists, Type 2 Diabetes

Atisso C.M., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Dyal L., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Munoz E.G.C., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T.